3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
24
Prostatic Neoplasms, Castration-Resistant
4
Prostatic Diseases
3
Neoplasm Metastasis
3
Metastatic Castration-resistant Prostate Cancer
3
Urogenital Neoplasms
2
Triple Negative Breast Neoplasms
2
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Male Urogenital Diseases
2
Genital Diseases, Male
2
Adenocarcinoma
2
Urogenital Diseases
1
Sleep Initiation and Maintenance Disorders
1
Prostate Cancer Metastatic
1
Non-metastatic Castration-resistant Prostate Cancer
1
Neoplasms by Site
1
Neoplasms
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer (mCRPC)
1
High-Risk Localized Prostate Cancer
1
Fatigue
1
Depression
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Bulbo-Spinal Atrophy, X-Linked
1
Advanced Solid Tumor
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
darolutamide
×
Clear all
NCT07103018
2026-03-23
STRIKE-001
K36 Therapeutics, Inc.
Phase 1
Recruiting
144 enrolled